Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer

Core Viewpoint - Alpha Tau Medical Ltd. has received FDA approval for a pilot study using its Alpha DaRT technology to treat locally recurrent prostate cancer, marking its fifth active Investigational Device Exemption (IDE) in the U.S. [1][3] Group 1: Company Developments - The FDA's approval allows Alpha Tau to expand its Alpha DaRT technology into the U.S. market for prostate cancer treatment [1] - The clinical trial will enroll up to 12 patients with locally recurrent prostate cancer, focusing on safety and efficacy evaluations [2] - Alpha Tau aims to provide a new local salvage therapy option for patients facing limited alternatives [3] Group 2: Technology Overview - Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) utilizes radium-224 to deliver targeted alpha-radiation to solid tumors, minimizing damage to surrounding healthy tissue [4] - The technology was developed by researchers from Tel Aviv University and is focused on treating solid tumors [5]